am.wikstrom

TL2 · Rennes

Contributes reviews on supplier material. Based in Rennes.

Joined 6 November 2024 · last posted 2d

77 posts, newest first. Showing up to 150.

Why the Start Here categories exist, and what they are not for Replied, post #40 · Start Here › Welcome · 26 Jul 2026 · 9 likes The most useful thing anyone has posted about Start in this category was a table of what had been measured and by whom. That is what I would want again.
Tracking intake honestly when appetite is absent Replied, post #109 · Nutrition & Training › Protein & intake · 22 Jul 2026 · 0 likes Protein supplements: whey, casein, and plant-based protein powders can help hit targets when whole-food intake is limited by appetite. Protein quality (all essential…
Coming back to: Delayed gastric emptying and oral medication absorption: which drugs… Replied, post #45 · Practice › Interactions · 20 Jul 2026 · 19 likes I had written a reply contradicting post #43 and deleted it. Here is what survived. The most defensible general position in this subcategory: identify the plausible…
[2026 update] Interpreting a result that disagrees with the supplier's certificate Replied, post #95 · Sourcing › Independent verification · 16 Jul 2026 · 1 like I have no financial interest in anything named in this thread and I want to say so before I comment on Interpreting a result, because it is the sort of subject where it…
Pooling trials with different estimands Replied, post #70 · Evidence › Meta-analyses · 4 Jul 2026 · 0 likes Pooling trials with different estimands: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would…
Request: a per-category review queue Replied, post #77 · Meta › Feature requests · 3 Jul 2026 · 15 likes Seconded. It reads as careful rather than confident, which is the right register.
Retatrutide mass and identity: what a report should show Replied, post #6 · Compounds › Retatrutide · 29 Jun 2026 · 17 likes I read post #2 twice before replying, because I had assumed the opposite. Reading this retatrutide mass and identity thread as someone who came in with a fixed view:…
Coming back to: Specificity, linearity, accuracy, precision, range, robustness — with… Replied, post #69 · Analytics › Method validation · 27 Jun 2026 · 19 likes Post #68 is the version of this I will quote in future. One addition. Linearity across the working range is a routine demonstration and it constrains how far a result…
Second pass at: Metformin co-administration and additive GI effects Replied, post #133 · Practice › Interactions · 25 Jun 2026 · 0 likes Adding the measurement that post #131 says would settle it. I have three months of notes on Metformin co-administration and the honest summary is that the trend is real…
Bioimpedance and hydration: why the number moves Replied, post #64 · Outcomes › Body composition · 22 Jun 2026 · 0 likes Two people in this thread mean different things by bioimpedance and hydration and are disagreeing about the definition while believing they are disagreeing about the…
An appeal that succeeded, with the letter structure — the long version Replied, post #62 · Access › Insurance & coverage · 7 Jun 2026 · 3 likes Taking post #59 at face value and following it one step further. Nothing here is legal or medical advice, and appeal processes differ enough by jurisdiction and payer…
Comparing prices across jurisdictions without misleading yourself Replied, post #45 · Access › Pricing · 6 Jun 2026 · 0 likes Worth separating comparing prices across jurisdictions as a question about the compound from comparing prices across jurisdictions as a question about the…
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #3 · Access › International · 6 Jun 2026 · 19 likes The opening post put the caveat in the right place and I want to underline it. Where a compound is approved under a different trade name in another market, searching…
Revisiting: Taste changes and food aversion, reported and discussed Replied, post #2 · Practice › Side effects · 4 Jun 2026 · 14 likes Fatigue: commonly reported, frequently multifactorial. It is worth asking whether other factors have changed (sleep, training volume, diet adequacy, hydration) before…
Run-in periods and the population they select Replied, post #129 · Evidence › Trials · 2 Jun 2026 · 5 likes Grateful for the specificity. Vague answers to this question are what sent me looking.
Endotoxin and why it is a separate question from purity — what changed since Replied, post #32 · Analytics › Impurities & related substances · 30 May 2026 · 16 likes Post #29 is right about the mechanism and I think understates the practical bit. The honest reading of a purity figure: it is an upper bound on how much of what the…
Official shortage notices and what they authorise Replied, post #73 · Access › Shortages · 28 May 2026 · 0 likes Dose hold versus tapering: if a temporary shortage forces a gap, holding your dose and resuming when supply returns is different from gradually tapering. The two are…
How this community labels and discusses unrefereed work — the long version Replied, post #18 · Evidence › Preprints · 13 May 2026 · 0 likes Thank you for taking the time. That was more work than a reply usually is.
GLP-1 receptor distribution: central and peripheral Replied, post #44 · Pharmacology › Receptor biology · 5 May 2026 · 10 likes Receptor distribution explains the side-effect profile better than anything else. GLP-1 receptors in the gastrointestinal tract and the area postrema account for most…
Reconstituting a multi-strength kit without mixing yourself up — what changed since Replied, post #10 · Practice › Reconstitution · 1 May 2026 · 13 likes The most useful reply I ever got about Reconstituting a multi-strength kit was a request to state my units. It sounds like pedantry and it has saved me twice.
[2026 update] 0.3 mL versus 0.5 mL versus 1 mL barrels: resolution matters Replied, post #76 · Devices › Syringes & needles · 1 May 2026 · 3 likes That reframing is the whole thing. The facts I already had.
Follow-up: Comparing two chromatograms from different laboratories, properly Replied, post #13 · Analytics › HPLC & UHPLC · 15 Apr 2026 · 0 likes Reversed-phase separates on hydrophobicity. A peptide is retained on a non-polar stationary phase and eluted by increasing organic solvent. For peptides the mobile…
Type 2 diabetes and the largest part of the evidence base Replied, post #56 · Clinical › Comorbidities · 5 Apr 2026 · 9 likes Appreciated. The plain phrasing does more work here than a longer post would.
Grapefruit: why this class is not the class that cares Replied, post #106 · Practice › Interactions · 1 Apr 2026 · 6 likes Where I part company with post #102, and it is a narrow parting. Distinguishing three things in the grapefruit discussion that keep getting used interchangeably: the…
CJC-1295 with and without DAC: what the modification does Replied, post #23 · Compounds › Secretagogues & GH axis · 30 Mar 2026 · 9 likes A mass result for a short peptide is more discriminating than for a long one, because a single residue difference is a larger proportion of the total. That makes…
[2026 update] Does a peptide degrade silently, with no visual change? Replied, post #37 · Practice › Storage & stability · 22 Mar 2026 · 28 likes Thank you — that answers what I came here to find out.
Ultrasound and skinfolds: operator dependence in practice — what changed since Replied, post #24 · Outcomes › Body composition · 13 Mar 2026 · 12 likes I had written a reply contradicting post #20 and deleted it. Here is what survived. Percentage body fat is a ratio, so it changes when either component changes. A…
Micro-titration: a disputed topic, argued properly Replied, post #44 · Practice › Dosing & titration · 9 Mar 2026 · 0 likes Picking up post #42: that is the part I would want checked first. The maximum studied dose is a fact about the trial and not a ceiling on the molecule. It is also the…
Molecular mass of semaglutide and why the figure differs between sources Replied, post #6 · Compounds › Semaglutide · 16 Feb 2026 · 0 likes The oral formulation is a genuinely different pharmaceutical problem from the injectable and shares only the active molecule. Absorption enhancers, fasting requirements…
Request: export my own posts — one year on Replied, post #45 · Meta › Feature requests · 10 Feb 2026 · 0 likes Use case: explain why you think the feature would help. "I would use this to..." makes the request concrete.
Follow-up: Search filters: what is missing Replied, post #24 · Meta › Site feedback · 31 Jan 2026 · 6 likes On post #22 — agreed on the reasoning, with one qualification. Navigation problems: if you cannot find something you expected to exist, or the path to it is unclear,…
Which panel is worth repeating and which is worth ignoring — a second dataset Replied, post #64 · Clinical › Bloodwork · 30 Jan 2026 · 15 likes Panel is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until someone says which one is…
Filter needles: when they help and what they cost you Replied, post #34 · Devices › Syringes & needles · 24 Jan 2026 · 8 likes Gauge is the outside diameter and higher numbers are thinner. Thinner needles hurt less and draw more slowly, which is the entire trade. Flagging that the sources on…
Distinguishing expected GI effects from something that needs urgent attention Replied, post #93 · Practice › Side effects · 13 Jan 2026 · 0 likes Adding the measurement that post #90 says would settle it. The relationship between symptom burden and outcome is not what people assume. Feeling worse is not evidence…
A partial dose because the pen emptied mid-injection Replied, post #3 · Practice › Administration · 6 Jan 2026 · 33 likes Where I part company with the opening post, and it is a narrow parting. Before the thread moves on from partial dose because the pen — what is the sample size behind…
Tracking that stops updating and then resumes — the long version Replied, post #61 · Sourcing › Logistics · 5 Jan 2026 · 14 likes Where I part company with post #59, and it is a narrow parting. Import restrictions by jurisdiction: what is legal to import for personal use varies enormously by…
The decimal-point error, and the habit that catches it Replied, post #22 · Practice › Reconstitution · 14 Dec 2025 · 0 likes Where the decimal-point error discussion usually stalls is that nobody wants to say "I do not know" and everyone is willing to say "it varies". Those are the same…
Promotion criteria, and the one that stops most nominations — the long version Replied, post #98 · Documentation › Doc review · 22 Nov 2025 · 18 likes The arithmetic in post #95 is right; the assumption feeding it is the part to check. Where the review finds the content is right but the framing overstates it, that is…
Personal import allowances, compared — a second dataset Replied, post #19 · Access › International · 8 Nov 2025 · 30 likes One more thing on Personal import allowances that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that,…
Titles that describe the question, not the situation Replied, post #118 · Start Here › How to Ask · 10 Oct 2025 · 7 likes Nobody minds being asked to explain a term. The people who use them most are the quickest to define them, and a question that stops to ask is usually a question that…
Cagrilintide's dosing interval and the pharmacokinetics behind it Replied, post #19 · Compounds › Cagrilintide & amylin analogues · 1 Oct 2025 · 11 likes Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably…
Revisiting: Reading a denial letter as a specification for your appeal Replied, post #137 · Access › Insurance & coverage · 27 Sep 2025 · 0 likes On Reading a denial letter, I would rather understate and be corrected upward than overstate and be quoted. That is a house style here and it is a good one.
What the GIP component of tirzepatide is thought to contribute, and how confident we can… Replied, post #37 · Compounds › Tirzepatide · 8 Sep 2025 · 12 likes Two claims get bundled together under GIP component of tirzepatide and they need separating. The descriptive one — this is what was observed — is usually well…
[2026 update] What we do not know about retatrutide, listed explicitly Replied, post #81 · Compounds › Retatrutide · 6 Sep 2025 · 2 likes Picking up post #80: that is the part I would want checked first. Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one…
When a preprint is the best available evidence and we say so Replied, post #74 · Evidence › Preprints · 19 Aug 2025 · 15 likes This follows post #72 rather than contradicting it. A preprint with the data and code attached is frequently more checkable than a published paper without them.…
The "under review" status pill and when a moderator applies it — a second dataset Replied, post #21 · Evidence › Preprints · 17 Aug 2025 · 0 likes Answering the question post #17 raises rather than the one it answers. The honest position on most preprints in this field is that they are interesting and provisional,…
Pages past their review date, listed Replied, post #18 · Meta › Wiki maintenance · 16 Aug 2025 · 18 likes On post #16 — agreed on the reasoning, with one qualification. That matches how I use it. The general statement is what you check afterwards, not what you arrive for.…
Power cut for eleven hours: how I assessed it afterwards Replied, post #21 · Practice › Storage & stability · 12 Aug 2025 · 3 likes Clarity is a weak test. A solution can lose a significant fraction of its active content to degradation or adsorption while remaining perfectly clear.
[2026 update] Cardiovascular risk: reading the outcome trials as a set Replied, post #80 · Clinical › Comorbidities · 27 Jul 2025 · 10 likes Interactions between comorbidities: diabetes and kidney disease together change the risk calculation for hypoglycemia and for medication clearance. They are not…
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one… Started this topic · Compounds › Retatrutide · 17 Jul 2025 · 56 likes The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on I will give what I have already checked below…
A field-by-field walk through a certificate of analysis Replied, post #58 · Analytics › COA interpretation · 16 Jul 2025 · 2 likes The arithmetic in post #57 is right; the assumption feeding it is the part to check. What I would check first on field-by-field walk through a certificate is whether…
Discussing something you have already been doing — the long version Replied, post #17 · Clinical › Prescriber conversations · 12 Jul 2025 · 19 likes Prescription logistics: confirm whether it will be filled locally, requires mail order, or will be prescribed off-label and needs a compounding pharmacy. Different…
Revisiting: Why I ask for the gradient before I discuss the number Replied, post #11 · Analytics › HPLC & UHPLC · 8 Jul 2025 · 8 likes Worth separating two things that post #9 runs together. Gradient slope is the single biggest driver of apparent purity differences. A shallower gradient over a longer…
Coming back to: Semaglutide half-life: where the 165 to 184 hour figure comes from Replied, post #51 · Compounds › Semaglutide · 2 Jul 2025 · 30 likes Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason…
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly Replied, post #123 · Compounds › Tirzepatide · 29 Jun 2025 · 14 likes Agreed, and I will stop repeating the version of this I had been repeating.
Half-life, steady state, and accumulation worked through Replied, post #114 · Pharmacology › Pharmacokinetics · 14 Jun 2025 · 2 likes Where I have landed on half-life, having got it wrong once in public: the direction is clear, the magnitude is not, and anyone quoting a precise magnitude has borrowed…
Obstructive sleep apnoea and a hard endpoint in this class Replied, post #105 · Clinical › Comorbidities · 5 Jun 2025 · 0 likes Everything in post #103 holds. The case it does not cover is the one I have. Genuine question rather than a rhetorical one: has anyone here actually observed…
A well-designed study with a badly written abstract Replied, post #34 · Evidence › Study critique · 20 Apr 2025 · 32 likes My experience of well-designed study contradicts the reply above. I am posting it as a data point rather than as a refutation, because one person's experience is…
Documenting a supplier's response to a discrepancy — does this still hold? Replied, post #36 · Sourcing › Vendor reports · 30 Mar 2025 · 10 likes Dosing and purity: a vial that is 99% pure might contain 80% of its label claim if the other mass is water, counter-ion, and excipient. Purity and content are…
Why cagrilintide alone is discussed so much less than in combination Replied, post #53 · Compounds › Cagrilintide & amylin analogues · 28 Mar 2025 · 9 likes The phase 3 combination programme is where the clinically interesting numbers will come from. Phase 2 established that the combination does something; the size of it in…
Reading an MS report that only gives you a single number Replied, post #32 · Analytics › Mass spectrometry · 19 Mar 2025 · 0 likes Positional isomers and epimers are mass-identical. Any argument that a mass result rules them out is wrong, and it is the commonest overclaim in this subcategory. I…
Charge states for a 4 kDa peptide, worked through Replied, post #15 · Analytics › Mass spectrometry · 3 Mar 2025 · 0 likes Charge states has a well-known answer and a correct answer, and the interesting work is establishing that they are the same. Nobody has done that here yet.
[2026 update] Lipid changes during rapid weight loss: the expected trajectory Replied, post #39 · Clinical › Bloodwork · 31 Jan 2025 · 5 likes This follows post #36 rather than contradicting it. Reporting rather than recommending, on Lipid changes during rapid weight. What happened is above. Whether it should…
Feature request: should a dose-equivalence tool exist at all? Replied, post #20 · Data & Tools › Calculators · 27 Jan 2025 · 23 likes I would be cautious about generalising from the feature request example above. It is a good example. It is one example.
Distinguishing a deletion sequence by mass alone Replied, post #21 · Analytics › Mass spectrometry · 26 Jan 2025 · 3 likes Post #17 put the caveat in the right place and I want to underline it. Distinguishing a deletion sequence is a good example of a question where the honest answer is…
Revisiting: Holding a dose indefinitely: is there a documented downside? Replied, post #26 · Practice › Dosing & titration · 12 Jan 2025 · 0 likes Reaching a dose and staying there for a year: the question of whether a stable dose remains effective over years is mostly answered by the withdrawal trials and by…
Revisiting: Bug report: the reconstitution calculator and a rounding edge case Replied, post #43 · Data & Tools › Calculators · 7 Jan 2025 · 0 likes Where I part company with post #41, and it is a narrow parting. The reconstitution calculation is total mass divided by total volume for concentration, then dose…
Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Replied, post #77 · Compounds › Semaglutide · 4 Jan 2025 · 11 likes Post #75 describes the usual case. This is about the unusual one. Injection site does not appear to matter much for semaglutide exposure. The published comparisons of…
Books and papers worth reading that are not about this at all Replied, post #8 · Lounge › Off topic · 2 Jan 2025 · 21 likes The thing about books and papers that took me longest to accept is that a plausible mechanism is not evidence of an effect. It is a reason to look, not a result.
Second pass at: Regression to the mean in progress reports Replied, post #6 · Research Methods › Statistics · 22 Dec 2024 · 29 likes Adding the measurement that post #5 says would settle it. Regression to the mean explains a large share of apparent improvements in anything selected for being extreme.…
[2026 update] New subcategory: rationale and scope Replied, post #83 · Meta › Announcements · 21 Dec 2024 · 1 like Post #81 describes the usual case. This is about the unusual one. The edit is clearer. For anyone arriving now, read the edited version — the confusion in the replies…
Reading a preclinical wound-healing model and its relevance to a human tendon Replied, post #74 · Compounds › Repair & healing peptides · 17 Nov 2024 · 1 like Reported local reactions are common enough in first-hand accounts here to be worth mentioning and are not characterised in any published series. I have said this before…
People with a low starting BMI: where the evidence stops Replied, post #5 · Clinical › Special populations · 2 Oct 2024 · 32 likes The arithmetic in post #4 is right; the assumption feeding it is the part to check. Extrapolating a point estimate to somebody well outside the enrolled range should be…
Progressive overload when the scale is falling — one year on Replied, post #108 · Nutrition & Training › Resistance training · 30 Sep 2024 · 1 like Answering the question post #106 raises rather than the one it answers. Cardiovascular work has its own benefits and is not a substitute for a resistance stimulus for…
Progressive overload when the scale is falling — one year on Replied, post #83 · Nutrition & Training › Resistance training · 23 Sep 2024 · 25 likes Answering the question post #79 raises rather than the one it answers. Reduced appetite makes fuelling a session harder, and that is a practical problem with practical…
Revisiting: US compounding rules and how they changed Replied, post #6 · Regional › North America · 25 Aug 2024 · 0 likes Quietly grateful for the plain phrasing. Not every thread gets that.
How this community labels and discusses unrefereed work Replied, post #9 · Evidence › Preprints · 8 Jun 2024 · 7 likes Second-hand on community labels, so weight it accordingly — someone whose method I trust told me this and I have not verified it myself.